Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Horizon Therapeutics Public Ltd Co | d791158d8k.htm |
| EX-10.3 - EX-10.3 - Horizon Therapeutics Public Ltd Co | d791158dex103.htm |
| EX-3.1 - EX-3.1 - Horizon Therapeutics Public Ltd Co | d791158dex31.htm |
| EX-4.1 - EX-4.1 - Horizon Therapeutics Public Ltd Co | d791158dex41.htm |
| EX-10.4 - EX-10.4 - Horizon Therapeutics Public Ltd Co | d791158dex104.htm |
| EX-99.2 - EX-99.2 - Horizon Therapeutics Public Ltd Co | d791158dex992.htm |
| EX-99.4 - EX-99.4 - Horizon Therapeutics Public Ltd Co | d791158dex994.htm |
| EX-10.1 - EX-10.1 - Horizon Therapeutics Public Ltd Co | d791158dex101.htm |
| EX-99.3 - EX-99.3 - Horizon Therapeutics Public Ltd Co | d791158dex993.htm |
| EX-99.1 - EX-99.1 - Horizon Therapeutics Public Ltd Co | d791158dex991.htm |
| EX-10.2 - EX-10.2 - Horizon Therapeutics Public Ltd Co | d791158dex102.htm |
| EX-14.1 - EX-14.1 - Horizon Therapeutics Public Ltd Co | d791158dex141.htm |
Exhibit 16.1
September 19, 2014
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated September 19, 2014, of Horizon Pharma Public Limited Company and are in agreement with the statements contained under Item 4.01(a). We have no basis to agree or disagree with other statements of the registrant contained therein.
Very truly yours,
/s/ Habif, Arogeti & Wynne LLP